Traffic barrier

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 11, 2023
Medicine, Observation, Research, Safety, CDK, Therapy, Toxicity, Cohort, University, Disease, Everolimus, Learning, Brain, Patient, Ribociclib, Division, Pharmacokinetics, Hematology, Neutropenia, Menarini, Diarrhea, Nausea, Cancer, Toxic leukoencephalopathy, Traffic barrier, Pharmaceutical industry, MD

Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of metastatic sites, show a tolerable and manageable safety profile with favorable preliminary efficacy.

Key Points: 
  • Encouraging results from phase 1 ELECTRA, evaluating ORSERDU in combination with abemaciclib regardless of metastatic sites, show a tolerable and manageable safety profile with favorable preliminary efficacy.
  • Both the ELEVATE and ELECTRA studies were designed with the objective to overcome different resistance mechanisms and enhance patient outcomes with combination treatment options.
  • Data was presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • "We look forward to learning more about ORSERDU's role in combination settings and its potential across the spectrum of metastatic breast cancer."

Cordance Medical Announces Agreement with Stanford Medicine's Airan and Williams Labs for Precision Neuropsychiatry with Ultrasonic Drug Uncaging Technology

Retrieved on: 
Thursday, December 7, 2023
DRS, Neuropsychiatry, Brain, Airan, Research, Associate professor, Chronic pain, Psychiatry, Assistant professor, Nanoparticle, Patient, Medicine, Neurology, BBB, Neuro, Pi, Ketamine, Health, Diffusion, Traffic barrier, Medical imaging, Cordance

MOUNTAIN VIEW, Calif., Dec. 7, 2023 /PRNewswire/ -- Cordance Medical, a pioneering medical technology company focused on non-invasive brain treatments, is pleased to announce a new strategic agreement with Stanford Medicine, working with radiologist Dr. Raag Airan, Assistant Professor, and neurologist-psychiatrist Dr. Nolan Williams, Associate Professor, Stanford Medicine. This collaboration will combine Cordance's breakthrough NeuroAccess™ device with Dr. Airan's novel nanoparticle drug development to establish a new standard for precision medicine in neurology and psychiatry. Dr. Airan is also an Advisor with Cordance Medical.

Key Points: 
  • The combined expertise of Cordance and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
  • This method enables focal noninvasive drug delivery with the Airan Lab's pioneering technology of Ultrasonic Drug Uncaging, leveraging the capabilities of NeuroAccess beyond its original function of blood-brain barrier (BBB) opening.
  • "With this agreement, we're taking a critical step forward in the field of precision neuropsychiatry," said Ryan Dittamore, CEO of Cordance.
  • Airan and Williams at Stanford Medicine said, "Our labs have made significant strides in developing ultrasonic drug uncaging using drug-loaded nanoparticles that can be triggered using short, low-intensity ultrasound pulses.

Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson's Disease Conference

Retrieved on: 
Monday, December 4, 2023
Parkinson's disease, Lung, Brain, SAN, Therapy, CSF, Kidney, OrbiMed, Conference, LRRK2, Fiat 500X, Cerebrospinal fluid, Traffic barrier, Pharmaceutical industry

The results were unveiled at the prestigious Future of Parkinson's Disease Conference.

Key Points: 
  • The results were unveiled at the prestigious Future of Parkinson's Disease Conference.
  • LRRK2, recognized as a crucial drug target in Parkinson's disease, plays a major role in the pathogenesis of the condition.
  • Inhibiting LRRK2 activity has emerged as a promising disease-modifying therapeutic strategy, and several drug candidates have achieved clinical status.
  • The BT-0267 candidate has an efficient blood-brain barrier penetration while minimized peripheral exposure as well as has a superior overall safety profile.

The Paul G. Allen Family Foundation awards $10.5 million to new Allen Distinguished Investigators

Retrieved on: 
Tuesday, November 21, 2023
Medicine, Brain, Genetics, Research, Behavior, Reproduction, Hormone, Immune system, Inflammation, Testosterone, Allen Institute, EVS, Immunity, Microscopy, B cell, Disease, Protein, Learning, Mortality, Cardiovascular disease, Glossary of biology, Extracellular vesicle, Lipoprotein, Male, Neuron, Map, Animal, Machine learning, Health, COVID-19, Seminal vesicles, Ageing, Administration, Infection, Estradiol, Mammal, Neuroendocrinology, EV, DSM-IV codes, Skin, Female, Innovation, Cell, Biology, Traffic barrier, Pharmaceutical industry, Vaccine, Fireworks, Birth control, Science

18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology

Key Points: 
  • 18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology
    The Paul G. Allen Family Foundation will award $1.5 million to seven research projects which 18 researchers will lead.
  • "Our two newest cohorts of Allen Distinguished Investigators are using innovative technologies and unprecedented ambition to pioneer new frontiers in the fields of sex hormones and extracellular vesicles.
  • said Kathy Richmond , Ph.D., M.B.A., Executive Vice President and Director of the Frontiers Group and the Office of Science and Innovation at the Allen Institute.
  • Including the new awards, a total of 130 Allen Distinguished Investigators have been appointed during the past 12 years.

EQS-News: invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

Retrieved on: 
Friday, December 15, 2023
Immune system, Survival, MD, Brain, Harvard Medical School, Neuro-Oncology (journal), Science, Cancer, Research, Cytokine, European Association of Urology, Doctor of Philosophy, Temozolomide, Radiation, Gesellschaft mit beschränkter Haftung, Dana–Farber Cancer Institute, Patient, Traffic barrier, Glioblastoma, Biotechnology, Pharmaceutical industry, Medical imaging, Medicine, Boston

Preclinical study will be conducted by Dr. David Reardon’s research group

Key Points: 
  • Preclinical study will be conducted by Dr. David Reardon’s research group
    Vienna, Austria and Boston, MA USA, 9 November 2023: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
  • The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
  • Among these, some compounds can cross the blood-brain barrier and enter the glioblastoma micro-environment to initiate anti-tumoral immune reactions.

'News overload': how a constant stream of violent images affects your brain

Retrieved on: 
Thursday, November 9, 2023
Time, Amygdala, Technology, Heart rate, History, Human, Blood pressure, Prefrontal cortex, Pressure, Vein, Habit, News, Atmosphere, Attention, Research, Trauma, Learning, Traffic barrier, Crusades, City, Memory, Risk, Animal, Prisoner, Hormone, Population, Terror, Attack, Death, Communication, Cognition, Entertainment, Tourism, Birth control

Even then, they would only have heard accounts of the events, without images or videos to reproduce exactly what happened.

Key Points: 
  • Even then, they would only have heard accounts of the events, without images or videos to reproduce exactly what happened.
  • In today’s world, omnipresent communication technology means the spread of horrific images is all but impossible to escape.
  • We experience this now, for example, with images from Israel and Gaza, and other wars and attacks in recent years.

Images that release cortisol

  • Even when viewed through a phone screen, experiencing an extremely violent situation activates the sympathetic branch of our nervous systems, which governs our “fight or flight” response.
  • Our bodies react to these images by secreting hormones into the bloodstream including adrenaline, noradrenaline and cortisol, commonly known as the stress hormone.
  • If they become chronic, they can cause serious health problems in the long run, as has been common knowledge for decades.

Poor memory and a loss of control

  • In acutely stressful situations the hippocampus’ role in memory becomes inhibited, and the prefrontal cortex ceases to exercise control.
  • These changes are, in principle, intended to help us cope with specific stressful situations in the short term.
  • When we face a threat the priority is to react quickly, not taking time to remember similar events and analyse contextual factors.
  • This is essentially because chronic stress causes problems for our learning and memory, affecting three areas which are worth exploring in more detail: precision, flexibility and reconsolidation.


Francisco Javier Saavedra Macías no recibe salario, ni ejerce labores de consultoría, ni posee acciones, ni recibe financiación de ninguna compañía u organización que pueda obtener beneficio de este artículo, y ha declarado carecer de vínculos relevantes más allá del cargo académico citado.

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

Retrieved on: 
Thursday, November 9, 2023
Survival, Temozolomide, Harvard Medical School, Dana–Farber Cancer Institute, Gesellschaft mit beschränkter Haftung, Biotechnology, MD, Cytokine, Doctor of Philosophy, Research, Traffic barrier, Science, Immune system, Cancer, Radiation, European Association of Urology, Brain, Neuro-Oncology (journal), Patient, Glioblastoma, Pharmaceutical industry, Medical imaging, Medicine

Preclinical study will be conducted by Dr. David Reardon’s research group

Key Points: 
  • Preclinical study will be conducted by Dr. David Reardon’s research group
    VIENNA, Austria and BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
  • The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
  • After seeing the initial promising preclinical data on INV501 in solid tumors presented by invIOs, we are excited to test this small molecule that crosses the blood-brain barrier in glioblastoma models.

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Research, The Michael J. Fox Foundation, AD, PD, Immune tolerance, Food, Hypercholesterolemia, MJFF, Fast track (FDA), CSF, Pathology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Civil Service (United Kingdom), Traffic barrier, BBB, LDL, COVID-19, Antibody, Partnership, Comparison, PCSK9, Brain, Investment, Patient, Rare-earth element, Vaccine, Pharmaceutical industry, Cryptocurrency

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • This quarter, we have demonstrated proof of technology with our third clinical program, as well as our first proof of mechanism in our UB-312 program for Parkinson’s.
  • Results from the Phase 2a trial of UB-311 in patients with mild AD were published in The Lancet’s eBioMedicine in August 2023.
  • General and administrative expenses were $5.5 million and $7.3 million for the three months ended September 30, 2023, and 2022, respectively.

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Neurofilament light polypeptide, MPS II, CLE, Biomarker, Therapy, MS, BioRxiv, ETV, Ulcerative colitis, BBB, ALS, PTV, ATV, ROFN, Definitive, Traffic barrier, Hunter syndrome, Phase 10, Denali, MPS, Antibody, Biology, Safety, Patient, AFL, Plaque, Fluid mechanics, ASO, ARIA, RIPK1, Asos, Research, Cerebrospinal fluid, ISR, SGSH, DSM-IV codes, Nerve, Brain, Society, Total, OTV, N-sulfoglucosamine sulfohydrolase, Hunting, LUMA, Glycogen storage disease, Manuscript, UC, CSF, Amyloid-related imaging abnormalities, Takeda, COMPASS, Pathology, CNS, Sanfilippo, Neuroinflammation, Collaboration, Multiple sclerosis, Sanfilippo syndrome, IDS, Cognition, Mutation, SAN, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Biogen, LRRK2, Metabolism, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

CraniUS Named Company of the Year: Top Medtech Start-up 2023 by Medtech Outlook

Retrieved on: 
Tuesday, November 7, 2023
FDA, Traffic barrier, IND, Patient, Health, Myenteric plexus, Vaccine

BALTIMORE, Nov. 7, 2023 /PRNewswire/ -- CraniUS LLC, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain diseases, has been honored as Company of the Year - Top MedTech Startup 2023 by MedTech Outlook .

Key Points: 
  • BALTIMORE, Nov. 7, 2023 /PRNewswire/ -- CraniUS LLC, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain diseases, has been honored as Company of the Year - Top MedTech Startup 2023 by MedTech Outlook .
  • The company's patented NeuroPASS device is the first smart, refillable, and fully embedded medical device that effectively bypasses the blood-brain barrier and achieves long-term, convection-enhanced medicine delivery.
  • Mike Maglin, CEO of CraniUS, stated, "Being recognized among these exceptional innovators by Medtech Outlook is a great honor.
  • Bypassing the blood-brain barrier is a technological advancement that has the potential to significantly improve patient care."